{"denoms":[{"counts":[{"groupId":"BG000","value":"487"},{"groupId":"BG001","value":"483"},{"groupId":"BG002","value":"970"}],"units":"Participants"}],"groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.\n\nBiospecimen Collection: Undergo peripheral blood collection\n\nComputed Tomography: Undergo PET/CT or CT scan\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFilgrastim: Given SC or IV\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV\n\nPegfilgrastim: Given SC\n\nPositron Emission Tomography: Undergo PET/CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies\n\nRadiation Therapy: Receive radiation therapy\n\nVinblastine Sulfate: Given IV","id":"BG000","title":"Arm I (Chemotherapy, Nivolumab, Radiation)"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.\n\nBiospecimen Collection: Undergo peripheral blood collection\n\nBrentuximab Vedotin: Given IV\n\nComputed Tomography: Undergo PET/CT or CT scan\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFilgrastim: Given SC or IV\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPegfilgrastim: Given SC\n\nPositron Emission Tomography: Undergo PET/CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies\n\nRadiation Therapy: Receive radiation therapy\n\nVinblastine Sulfate: Given IV","id":"BG001","title":"Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"12.0","upperLimit":"83.7","value":"27.6"},{"groupId":"BG001","lowerLimit":"12.0","upperLimit":"81.7","value":"26.8"},{"groupId":"BG002","lowerLimit":"12.0","upperLimit":"83.7","value":"27"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"236"}],"title":"12-17"},{"measurements":[{"groupId":"BG000","value":"321"},{"groupId":"BG001","value":"318"},{"groupId":"BG002","value":"639"}],"title":"18-60"},{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"95"}],"title":">60"}],"title":"Age, Stratified"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"216"},{"groupId":"BG001","value":"210"},{"groupId":"BG002","value":"426"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"271"},{"groupId":"BG001","value":"273"},{"groupId":"BG002","value":"544"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"372"},{"groupId":"BG001","value":"361"},{"groupId":"BG002","value":"733"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"114"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"28"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"95"}]}],"title":"Other or unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"124"}]}],"title":"Hispanic"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Modified intent to treat group, in participants deemed ineligible are excluded."}